MedPath

Evaluation of melatonin tablets in patients with beta thalassemia major

Not Applicable
Conditions
Thalassemia.
?????????? ?????
D56.1
Registration Number
IRCT20201212049684N1
Lead Sponsor
Mazandaran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
36
Inclusion Criteria

Beta thalassemia major
Cases who are 18 years old or more
Treatment with standard iron chelators at least for two years
An unchanged treatment for 3 previous months before the beginning of the study
Serum ferritin level higher than 1000 ng/dL
Sleep quality index (PSQI)<5

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Estimating stress oxidative indexes as GSH,CAT,SOD and MDA. Timepoint: before treatment, at the end of Phase1 and at the end of the study. Method of measurement: Tests for oxidative stress with Spectrophotometry.
Secondary Outcome Measures
NameTimeMethod
Improvement of quality of sleep. Timepoint: Before treatment, at the end of Phase1 and at the end of study. Method of measurement: PSQI- Pittsburgh Sleep Quality Index questionnaire.
© Copyright 2025. All Rights Reserved by MedPath